Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of Combination Chemotherapy With Epirubicin , Cisplatin and Capecitabine (ECX) or Cisplatin and Capecitabine (CX) in Advanced Gastric Cancer
Brief Summary: Recently, 3-drug (ECX) and 2-drug (CX) combination chemotherapy involving capecitabine showed promising results in randomized clinical trials for advanced gastric cancer (AGC). The objective of the study is to evaluate the safety and activity of ECX and CX combination chemotherapy given as first-line therapy for AGC.


Options:
A: Arm Label: ECX; Type: EXPERIMENTAL; Interventions: Drug: Epirubicin, Drug: Cisplatin, capecitabine | Arm Label: CX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, capecitabine | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): ECX | Intervention Type: DRUG; Name: Cisplatin, capecitabine; Assigned to Arm(s): CX, ECX
B: Arm Label: Surgery + HIPEC + Systemic Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Oxaliplatin, Drug: Irinotecan, Drug: 5-Fluorouracil, Drug: Leucovorin, Procedure: Gastrectomy and/or metastasectomy | Arm Label: Systemic Chemotherapy Alone; Type: EXPERIMENTAL; Interventions: Drug: Oxaliplatin, Drug: Irinotecan, Drug: 5-Fluorouracil, Drug: Leucovorin | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: PROCEDURE; Name: Gastrectomy and/or metastasectomy; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy
C: Arm Label: Arm A, - Modified DCF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Arm Label: ARM B - Parent DCF with G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen | Arm Label: Arm C - Modifid DCF + Trastuzumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab | Intervention Type: DRUG; Name: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Assigned to Arm(s): Arm A, - Modified DCF | Intervention Type: DRUG; Name: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen; Assigned to Arm(s): ARM B - Parent DCF with G-CSF | Intervention Type: DRUG; Name: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab; Assigned to Arm(s): Arm C - Modifid DCF + Trastuzumab
D: Arm Label: Phase 2 Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: Cisplatin, Drug: Placebo | Arm Label: Phase 1b; Type: OTHER; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: AMG 102; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2 Arm C

Answer: A